Skip to main content

Potential Role of Statins in Re-Endothelialization

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or statins, are widely prescribed to lower cholesterol levels. Large clinical trials have demonstrated that statins reduce mortality and incidence of cardiovascular events. Although improvement of dyslipidemia is supposed to account for reduction of cardiovascular events by statin therapy, recent reports demonstrated that statins have lipid-independent benefits, so-called “pleiotropic effects”, including improvement of endothelial function, inhibition of inflammation, and augmentation of angiogenic response in ischemic tissues. Statins enhance re-endothelialization of injured arteries and inhibit atherosclerotic lesion development. Here, we overview the favorable effects of statins on endothelial cells and their progenitors and discuss clinical relevance of the vascular effects of statins in re-endothelialization and angiogenesis.





Keywords: Angiogenesis; Endothelium; Statin; atherosclerosis; progenitor

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/187152208784587917

Publication date: June 1, 2008

More about this publication?
  • Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in the medicinal chemistry and rational drug design for the discovery of new Immunology, Endocrine & Metabolic Agents. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Immunology, Endocrine & Metabolic medicinal chemistry.

    Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in Immunology, Endocrine & Metabolic drug discovery.
ben/iemamc/2008/00000008/00000002/art00006
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more